Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug‐Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open‐Label Studies in Healthy Subjects
Citations Over TimeTop 24% of 2021 papers
Abstract
Omecamtiv mecarbil (OM) is a cardiac myosin activator under development for the treatment of heart failure. The effect of CYP3A4 and CYP2D6 inhibition on OM pharmacokinetics and the potential for OM to induce CYP3A4 was assessed in 2 studies. Study 1, part A, assessed the effect of ketoconazole 200 mg on the pharmacokinetics of OM 10 mg in CYP2D6 extensive metabolizers (EMs; n = 8) or poor metabolizers (PMs; n = 8). Study 1, part B, assessed the effect of diltiazem 240 mg on the pharmacokinetics of OM 10 mg (EM; n = 8). Study 2 assessed the effect of OM 25 mg on the pharmacokinetics of midazolam 5 mg (n = 14). Coadministration with ketoconazole led to 51% and 31% increases in OM AUCinf in EM and PM subjects, respectively, whereas OM Cmax remained similar (3% higher and 14% lower for EM and PM subjects, respectively). No changes in OM pharmacokinetics were observed in EM subjects following coadministration with diltiazem. Midazolam AUCinf and Cmax decreased by 18% and 10%, respectively, when coadministered with OM. In conclusion, CYP3A4 and CYP2D6 inhibitors are unlikely to have a clinically significant effect on the pharmacokinetics of OM. In addition, OM is unlikely to have a clinically relevant effect on the pharmacokinetics of CYP3A4 substrates.
Related Papers
- → The Need for Multiple Doses of 400 mg Ketoconazole as a Precipitant Inhibitor of a CYP3A Substrate in an In Vivo Drug‐Drug Interaction Study(2009)22 cited
- → Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity(2012)37 cited
- → Dual Effects of Ketoconazole cis-Enantiomers on CYP3A4 in Human Hepatocytes and HepG2 Cells(2014)34 cited
- → Human Cytochrome P450: Metabolism of Testosterone by CYP3A4 and Inhibition by Ketoconazole(2004)33 cited
- → Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants(2021)20 cited